BioMedNewsBreaks

TuesdayFeb 13, 2024 1:07 pm

BioMedNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Releases Q2 2024 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is releasing its financial results for Q2 2024, the period ended Dec. 31, 2023. Highlights of the report include a 512% increase in year-to-date revenue, which reached $1,540,000 compared to $301,000 in the same period in 2023; a strong consolidated balance sheet with $37 million in cash and liquid investments; and a year-to-date FY 2024 gross margin increase of 46% from 38% during the same period in 2023. In addition, the company reported that its 1st Detect subsidiary reentered detection and nondetection testing with the U.S. Transportation Security Administration (“TSA”) for cargo…

Continue Reading

MondayFeb 12, 2024 2:50 pm

BioMedNewsBreaks — Astiva Health Marks Pivotal Phase in Transforming Healthcare Delivery

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities, was spotlighted as a significant player in the Medicare Advantage Prescription Drug (“MAPD”) sector in a recent episode of the Bell2Bell Podcast. “The episode featured an exclusive interview with Astiva Health’s Co-Founder and CEO Dr. Tri Nguyen, a renowned expert in internal medicine and cardiology. During the interview, Dr. Nguyen discusses Astiva Health’s journey since its inception in 2020 and its expansion plans. He shared insightful details about the company’s expansion to Los Angeles, San Bernardino and Riverside, marking a pivotal phase in…

Continue Reading

FridayFeb 09, 2024 3:05 pm

BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering

Immix Biopharma (NASDAQ: IMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, has closed on its previously announced underwritten public offering. The offering consisted of 5,535,055 shares of IMMX common stock, with each share sold at $2.71 per share. Gross proceeds from the offering to ImmixBio are projected to be an estimated $15 million, before standard deductions and expenses. According to the announcement, ImmixBio plans to use funds from the offering for its NXC-201 clinical trials as well as working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, acted as sole…

Continue Reading

FridayFeb 09, 2024 1:27 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal, CPA, CA, as the newest member of its executive team; Jagpal will serve as the company chief financial officer and corporate secretary, effective Feb. 20, 2024. Jagpal has garnered more than two decades of experience in financial leadership roles, primarily in the biotech industry. Most recently, she was vice president of Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS), where she was a key player in the company’s initial public offering process;…

Continue Reading

ThursdayFeb 08, 2024 3:15 pm

BioMedNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering

Revelation Biosciences (NASDAQ: REVB), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, recently announced the closing of its public offering. The offering consisted of 128,470 shares of the company’s common stock and 1,236,530 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 2,730,000 shares of its common stock, at an offering price to the public of $4.53 per share and associated warrant, or $4.5299 per pre-funded warrant and associated warrant. The warrants have an exercise price of $4.53 per share and…

Continue Reading

WednesdayFeb 07, 2024 2:23 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications. According to the announcement, the company is expanding through sponsored research agreements and material transfer agreements with several academic research collaborators. The programs will be focused on studying TUSC2, the tumor suppressor gene used in Genprex's lead drug candidate, REQORSA(R) (quaratusugene ozeplasmid), and NPRL2, another tumor suppressor gene. The company noted that new indications being evaluated include ALK-positive lung cancer as well as additional undisclosed programs. The expanded programs comprise research being conducted…

Continue Reading

WednesdayFeb 07, 2024 1:01 pm

BioMedNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Introducing Breakthrough Technology, Potential ‘Game Changer’ for the Cannabinoid Industry

Astrotech (NASDAQ: ASTC) is an instrumentation company that is focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM). Its subsidiary, AgLAB Inc., has breakthrough mass spectrometry technology in its AgLAB-1000-D2 mass spectrometer, a ruggedized factory floor analytical instrument designed to quickly and easily analyze complex chemical compounds found in organic plant materials, and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed to improve yields and bottom-line profits for hemp (‘CBD’) and cannabis (‘THC’) producers of CBD-THC oils by up to 30%... Using the AgLAB MVP solution, customers are now able to analyze the oils during processing…

Continue Reading

TuesdayFeb 06, 2024 3:11 pm

BioMedNewsBreaks – H.C. Wainwright & Co. Reiterates ‘Buy’ Rating, $6 PT on Longeveron (NASDAQ: LGVN)

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, was spotlighted in a recent H.C. Wainwright & Co. research report after the Company’s announcement about receiving a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for a patent application related to the use of Lomecel-B(TM) in Aging-related Frailty sufferers receiving vaccines for conditions such as COVID-19 and influenza. “In our view, the notice of patent allowance further bolsters the Lomecel-B(TM) intellectual property (‘IP’) estate and may serve as a life-cycle management (‘LCM’) tool should additional evidence support the agent’s value…

Continue Reading

TuesdayFeb 06, 2024 12:40 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Court of Appeal Dismisses Motion Brought by Dr. Raza Bokhari

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that the Court of Appeal for Ontario affirmed the judgment entered by the Superior Court of Justice in the amount of CDN $2.81 million, plus $175,000, plus interest. FSD Pharma was awarded an additional $5,000 in costs by the Court of Appeal in respect to Dr. Raza Bokhari’s failed motion for leave to appeal. The judgment confirmed arbitration awards in which the arbitrator dismissed…

Continue Reading

TuesdayFeb 06, 2024 12:25 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor Conference. The conference is scheduled for Feb. 26–27, 2024, in New York City. According to the company, CFO Ryan Confer will present at the two-day event. His presentation, which will begin at 1:30 p.m. ET on Feb. 26, will include an overview of the company's gene therapies for cancer and diabetes; Confer will also be available for in-person, one-on-one meetings with investors through the conference platform. To view the full press release,…

Continue Reading